Using Liquid Biopsy to Guide Adjuvant ICI for dMMR Tumors Available to Purchase

In a small investigator-initiated study, patients with early-stage mismatch repair–deficient solid cancers and minimal residual disease following surgery—determined by circulating tumor DNA—were found to benefit from pembrolizumab. The findings provide prospective evidence for liquid biopsy’s potential utility in guiding post-surgery immune checkpoint blockade for this population.